Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.
Hugo E R Ford, Andrea Marshall, John A Bridgewater, Tobias Janowitz, Fareeda Y Coxon, Jonathan Wadsley, Wasat Mansoor, David Fyfe, Srinivasan Madhusudan, Gary W Middleton, Daniel Swinson, Stephen Falk, Ian Chau, David Cunningham, Paula Kareclas, Natalie Cook, Jane M Blazeby, Janet A Dunn
Research output: Contribution to journal › Article › peer-review
Fingerprint
Dive into the research topics of 'Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial.'. Together they form a unique fingerprint.